Abequolixron (RGX-104)是一种具有口服活性的liver X receptor激动剂，可通过转录激活ApoE基因调节内源性免疫反应。 Information RGX-104 RGX-104 is a orally bioavailable liver X receptor agonist that modulates innate immunity via transcriptional activation of the ApoE gene. Targets LXR In vitro RGX-104 is an oral first-in-class LXR agonist that robustly induces ApoE expression resulting in innate-immune mediated anti-tumor activity. RGX-104 drives anti-tumor immunity by regulating the abundance and activity of myeloid derived suppressor cells (MDSC) and dendritic cells (DC). In vivo Antitumor activity has been demonstrated with RGX-104 monotherapy in several syngeneic and xenograft tumor models, including melanoma, lung cancer, ovarian cancer, GBM and others. The anti-tumor activity of LXR-agonism is related to constitutive upregulation of ApoE expression.